Oppenheimer Upgrades Amedisys To Outperform, Sets $40 Target
February 08, 2016 at 14:43 PM EST
Oppenheimer on Monday issued a report on Amedisys Inc (NASDAQ: AMED) amid signs that the company may be undervalued. The firm ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.